AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$CSTL

Oelschlager Kristen M sold $838K of CSTL (indirect holdings)

Oelschlager Kristen M (Chief Operating Officer) sold 24,602 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $34.06 ($33.69–$34.64, $0.84M total) across 3 trades over 2026-08-24 to 2026-08-25.

Original reporting
SEC EDGAR · Oelschlager Kristen M
Published Aug 26, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Bearish
medium confidence
Mentioned
$CSTL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLBearishLow
01

Why it matters

The disclosed sale provides new information on insider holdings and potential sentiment.

02

Market read

First public disclosure of a significant insider sale; may influence short-term trading decisions.

03

What to watch

COO retains a sizable stake, and the sale was executed via open market, not a forced liquidation.

Relevance 5/10Novelty 7/10Timing: filed Aug 26, 2026

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$CSTLBearishMedium confidence
Context

COO sold 24,602 shares for $837,864, reducing insider ownership to 72,649 shares.

Expected impact

Potential modest downside pressure in the near term.

Evidence & confidence

Sale size is moderate (~$0.8M) and the insider remains a significant holder, limiting impact.

Market effects

Sector

Minimal impact on biotech sector; typical insider sale.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily indicate negative outlook.

Key entities

  • Company
    Castle Biosciences Inc

    Biotech firm listed on NASDAQ under CSTL.

  • Person
    Kristen M. Oelschlager

    Chief Operating Officer of Castle Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min